What is the current Price Target for the Amgen stock?

The average Amgen target price is $405.45. This is 0.61% higher than the current stock price. The highest price target is 19.08%, the lowest is -43.61%. 34 Analysts have issued a price target Amgen 2027 .

How high will the Amgen stock rise?

No reliable answer can be given as to how high the Amgen stock will rise. The performance of stocks, including the Amgen stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Amgen stock today?

The performance of Amgen stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Amgen stock fall?

The decline in Amgen stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Amgen Forecast, price target & analysts

$402.98

0.01%

NYSE, Oct 05, 04:13 pm EDT. Closed.

ISIN

US0311621009

Symbol

AMGN

Reports

Quarter | Annual

Index

Dow Jones, NASDAQ-100

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts Ownership News Strategies

Amgen Target price 2026 - Analyst rating & recommendation

Amgen Classifications & Recommendation

Buy

47%

Hold

47%

Sell

Amgen Price Target

Target Price	$405.45
Price	$402.98
Potential	0.61%
Number of Estimates	34

	34 Analysts have issued a price target Amgen 2027 . The average Amgen target price is $405.45. This is 0.61% higher than the current stock price. The highest price target is $479.85 19.08% , the lowest is $227.25 43.61% .
	A rating was issued by 43 analysts: 20 Analysts recommend Amgen to buy, 20 to hold and 3 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2027 of 0.61% . Most analysts recommend the Amgen stock at Buy or hold.

Sales and Margin forecast 2026, 2027 to 2033

Already registered? Log in →

Quarter Annually

	Dec '25	2026 Estimates
Revenue Billion $	36.75	39.66
	9.95%	7.92%
EBITDA Margin	45.57%	55.90%
	0.13%	22.67%
Net Margin	20.98%	32.08%
	71.47%	52.89%

35 Analysts have issued a sales forecast Amgen 2026 . The average Amgen sales estimate is

unlock

. This is

unlock

than the revenue of the last 12 months(TTM). The highest sales forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics:

2025	$36.8b	9.95%
2026	$39.7b 7.92% unlock
2027	$41.0b 3.35% unlock
2028	$42.3b 3.21% unlock
2029	$43.1b 1.93% unlock
2030	$44.5b 3.28% unlock
2031	$45.7b 2.60% unlock
2032	$46.7b 2.14% unlock
2033	$46.9b 0.43% unlock

36 Amgen Analysts have issued a net profit forecast 2026. The average Amgen net profit estimate is

unlock

. This is

unlock

than the net profit for the last 12 months(TTM). The highest net profit forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future Net Margins:

2025	$7.7b	88.53%
2026	$12.7b 65.01% unlock
2027	$13.5b 5.95% unlock
2028	$14.2b 5.14% unlock
2029	$14.7b 3.79% unlock
2030	$15.5b 5.47% unlock
2031	$16.1b 3.93% unlock
2032	$16.9b 4.99% unlock
2033	$17.8b 5.10% unlock

2025	20.98%	71.47%
2026	32.08% 52.89% unlock
2027	32.89% 2.52% unlock
2028	33.51% 1.89% unlock
2029	34.12% 1.82% unlock
2030	34.84% 2.11% unlock
2031	35.29% 1.29% unlock
2032	36.28% 2.81% unlock
2033	37.96% 4.63% unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Already registered? Log in →

Quarter Annually

	Dec '25	2026 Estimates
Earnings Per Share $	14.23	23.52
	88.23%	65.28%
P/E		17.14
EV/Sales		6.59

36 Analysts have issued a Amgen forecast for earnings per share. The average Amgen EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$14.23	88.23%
2026	$23.52 65.28% unlock
2027	$24.92 5.95% unlock
2028	$26.20 5.14% unlock
2029	$27.20 3.82% unlock
2030	$28.68 5.44% unlock
2031	$29.81 3.94% unlock
2032	$31.30 5.00% unlock
2033	$32.89 5.08% unlock

Current	25.08	12.36%
2026	17.14 31.66% unlock
2027	16.17 5.66% unlock
2028	15.38 4.89% unlock
2029	14.82 3.64% unlock
2030	14.05 5.20% unlock
2031	13.52 3.77% unlock
2032	12.88 4.73% unlock
2033	12.25 4.89% unlock

Based on analysts' sales estimates for 2026, the Amgen stock is valued at an EV/Sales of

unlock

and an P/S ratio of

unlock

This results in the following potential growth metrics and future valuations:

Current	6.86	22.72%
2026	6.59 4.00% unlock
2027	6.37 3.24% unlock
2028	6.17 3.11% unlock
2029	6.06 1.89% unlock
2030	5.86 3.18% unlock
2031	5.72 2.53% unlock
2032	5.60 2.10% unlock
2033	5.57 0.43% unlock

Current	5.72	35.90%
2026	5.49 3.95% unlock
2027	5.32 3.24% unlock
2028	5.15 3.11% unlock
2029	5.05 1.89% unlock
2030	4.89 3.18% unlock
2031	4.77 2.53% unlock
2032	4.67 2.10% unlock
2033	4.65 0.43% unlock

Amgen...

Current Amgen Upgrades & Downgrades

Analyst	Rating	Action	Date
Scotiabank	Sector Outperform ➜ Sector Outperform	Unchanged	Sep 29 2026
HSBC	Buy ➜ Hold	Downgrade	Sep 10 2026
BMO Capital	Outperform ➜ Market Perform	Downgrade	Sep 08 2026
Cantor Fitzgerald	Neutral ➜ Neutral	Unchanged	Sep 08 2026
Wells Fargo	Equal-Weight ➜ Equal-Weight	Unchanged	Sep 04 2026
Piper Sandler	Overweight ➜ Overweight	Unchanged	Aug 20 2026
Argus Research	Buy ➜ Buy	Unchanged	Aug 19 2026

Analyst Rating	Date
Unchanged Scotiabank: Sector Outperform ➜ Sector Outperform	Sep 29 2026
Downgrade HSBC: Buy ➜ Hold	Sep 10 2026
Downgrade BMO Capital: Outperform ➜ Market Perform	Sep 08 2026
Unchanged Cantor Fitzgerald: Neutral ➜ Neutral	Sep 08 2026
Unchanged Wells Fargo: Equal-Weight ➜ Equal-Weight	Sep 04 2026
Unchanged Piper Sandler: Overweight ➜ Overweight	Aug 20 2026
Unchanged Argus Research: Buy ➜ Buy	Aug 19 2026

Discover more stocks with a high price target

NIO ADR 84.17%

Alibaba Group Holding Ltd 80.17%

Rheinmetall 66.50%

Tencent Holdings Ltd. 60.60%

Adyen 56.10%

BYD 49.89%

Uber Technologies 48.27%

TUI 46.72%

Infineon 45.44%

Siemens Energy 43.75%

Adidas 43.36%

Netflix 42.80%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now

The Apple stock at a glance with charts, current key metrics, news and stock analyses.

The Best Dividend Stocks in the Dividend Top Scorer list.

Stock Analyses of the Best Stocks Worldwide.

Start building wealth today

Amgen Forecast, price target & analysts